The safety and efficacy of umbilical cord blood mononuclear cells in individuals with spastic cerebral palsy: a randomized double-blind sham-controlled clinical trial

Table 3 The GMFM-66 and MAS mean difference within-groups (from baseline) and difference between groups

	Test of within-group effects (mean change from baseline)		Test of between-groups effects (mean change from control group)
	Control	MNC	MNC vs. Control
Outcomes	Mean [95% CI]	Mean [95% CI]	β	95% CI	P.v	Cohen's d [95%CI]
GMFM-66
T1	-0.02 [-4.79, 4.75]	9.24 [6.37, 12.11]^a	9.34	[3.58, 13.09]	0.001	0.87 [0.32, 1.41]
T2	2.03 [-2.97, 7.04]	9.17 [6.42, 11.92]	7.03	[2.07, 11.24]	0.004	0.73 [0.22, 1.23]
T3	-0.58 [-5.32, 4.15]	11.26 [8.39,14.13]	11.91	[5.40, 18.37]	< 0.001	0.94 [0.39, 1.48]
T4	1.23 [-3.33, 5.80]	9.62 [6.75,12.49]	7.10	[2.08, 12.76]	0.006	0.62 [0.07, 1.17]
MAS
T1	-0.53 [-0.87, -0.18]	-1.16 [-1.5, -0.85]	-0.62	[-1.01, -0.11]	0.014	0.37 [0.14, 0.89]
T2	-0.66[-0.99, -0.34]	-0.97 [-1.3, -0.66]	-0.31	[-0.77, 0.10]	0.132	0.11 [-0.37, 0.60]
T3	-0.69 [-1.03, -0.35]	-0.91 [-1.2,-0.58]	-0.21	[-0.87, 0.21]	0.086	0.22 [-0.31, 0.75]
T4	-0.28 [-0.62, 0.05]	-0.87 [-1.2, -0.54]	-0.58	[-1.18, -0.11]	0.016	0.36 [0.20, 0.87]

^aThe bold font shows that results are statistically significant
GMFM-66 Gross motor function measure-66, MAS Modified Ashworth scale, T1 One-month data collection, T2 Three-month data collection, T3 Six-month data collection, T4 One-year data collection

ISSN: 1471-2377